United Therapeutics and Liquidia settle their multi-case litigation with Liquidia agreeing to pay $330.4 million and cease marketing Yutrepia for PH-ILD.
SEC EDGAR, 2026-10-14: 8-K (Item 8.01, 9.01) — "cease and desist"
United Therapeutics and Liquidia settle their multi-case litigation with Liquidia agreeing to pay $330.4 million and cease marketing Yutrepia for PH-ILD.
Company: UNITED THERAPEUTICS Corp (UTHR) Filed: October 14, 2026, 8-K (Item 8.01, 9.01) Phrase: "cease and desist" — "Liquidia must also terminate cohorts of its ASCENT clinical trial of Yutrepia that are studying PH-ILD as promptly as practicable, cease and desist from publishing any new data, and cease and desist disseminating already-published data, from cohorts of the ASCENT trial that are studying PH-ILD until after the expiration of the ’327 patent." What the filing says: On October 13, 2026, United Therapeutics Corporation entered into a Settlement Agreement with Liquidia Technologies to resolve multiple pending patent, trade secrets, and antitrust lawsuits. Liquidia agreed to pay United Therapeutics a total of $330.4 million, consisting of $185.0 million within 30 business days for past damages and $145.4 million in two equal installments of $72.7 million in early 2027 for ongoing damages. Liquidia must immediately file with the FDA to remove the PH-ILD indication from its Yutrepia label, cease all marketing of Yutrepia for PH-ILD, and cease all sales of Yutrepia bearing the PH-ILD indication once the FDA approves the label amendment. United Therapeutics will also pay Liquidia $10.0 million to settle separate antitrust and contract litigation involving RareGen and Sandoz, subject to obtaining necessary third-party consents. Two ways it goes: A. Liquidia makes the required payments, the FDA approves the label amendment, and all covered lawsuits are dismissed with prejudice. B. Liquidia fails to make the payments or secure necessary third-party consents, resulting in the termination of the settlement and a resumption of litigation. Next date: January 31, 2027, the deadline for Liquidia to pay the first $72.7 million prospective infringement installment. Watch: Joint court filings for dismissal with prejudice and the FDA's decision on Liquidia's label amendment.